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Objectives: Research on the genetic basis of tinnitus is still in its 
first steps. A group of scientists dedicated to tinnitus genetics within 
European Tinnitus Network (TINNET) network recognize that further 
progress requires multicenter collaborative efforts for defining contrib-
uting genes. The purpose of the present work is to provide instructions 
regarding collection, processing, storage, and shipment of samples 
intended for genetic studies in auditory research.
Design: One part of the recommendations has a general character; another 
part is of particular importance for auditory healthcare practitioners such 
as otolaryngology physicians, audiologists, and general practitioners.
Results: We provide a set of instructions and various options for obtain-
ing samples. We give advice regarding sample processing, storage, and 
shipment and define the minimal and essential clinical information that 
should accompany the samples collected for genetic processing.
Conclusions: These recommendations offer a basis to standardize and 
optimize collaborations between geneticists and healthcare practitioners 
specialized in tinnitus and hearing disorders.
Key words: Auditory disorders, Biobanks, DNA, Genetics, Genomics, 
Hearing loss, RNA, Tinnitus.
(Ear & Hearing 2019;40;219–226)
BACKGROUND
Subjective tinnitus is thought to be triggered by maladaptive 
plasticity in the auditory pathway that occurs across varying 
degrees of hearing loss (Shore et al. 2016). Tinnitus may emerge 
under a variety of conditions, but most investigators conceptu-
alize it as the result of the auditory pathway employing com-
pensatory adjustments that increase neural gain and promote 
central disinhibition in response to a hearing disorder that may 
or may not be accompanied by a change in threshold (Schaette 
& McAlpine 2011).
Recent evidence obtained from concordance studies in 
twins supports moderate to high heritability of bilateral tinnitus 
among men, as well as women less than 40 years old (Maas et 
al. 2017). In contrast, unilateral tinnitus is found to be more 
related to environmental factors (Maas et al. 2017). Although 
additional concordance studies in independent twin cohorts 
need to be conducted to confirm these novel findings, this 
observation supports the notion that genetic factors are impor-
tant in the generation and persistence of tinnitus, and different 
biobanking initiatives have started to conduct genomic studies 
in tinnitus patients (Cederroth et al. 2017).
Genome-wide association studies (GWAS) have identified 
>24,000 single-nucleotide variants (SNVs) associated with 
common diseases or traits (MacArthur et al. 2017). Although 
the functional significance of many reliable SNV associa-
tions is unknown, bioinformatics integration of phenotype 
and genomic data has facilitated the understanding of disease 
mechanisms to establish targets for novel therapies. Exam-
ples of such approach include a GWAS conducted in major 
depression involving the HOMER1 gene, which mutant mice 
displayed evidence of depression and altered cortical-limbic 
circuitry (Rietschel et al. 2010); a collaborative effort of the 
International Multiple Sclerosis Genetics Consortium to dem-
onstrate a primary role for adaptive immunity (International 
Multiple Sclerosis Genetics Consortium 2011) or the identifi-
cation of missense SNVs in the MST1 gene in Crohn disease 
leading to reduced macrophage signaling (Pal & Moult 2015).
Two critical factors appear to contribute to the development 
and persistence of tinnitus: first, a hearing disorder, and second, 
the response of the cognitive and emotional neural networks to 
the tinnitus percept. It is rather well established that the interac-
tion between these two components leads to the end-phenotype of 
tinnitus (Noreña 2015). While tinnitus in general is perceived by 
approximately 15% of the population, nearly one tenth of affected 
individuals report it as bothersome. We believe that the design 
of clinical trials to find an effective treatment for tinnitus should 
involve deep phenotyping (Hall 2017). Deep phenotyping requires 
the acquisition of structured clinical information that facilitates 
the classification of patients into tinnitus subgroups (Lopez-Esca-
mez et al. 2016) and is one of the fundamental concepts of genet-
ics research and precision medicine (Müller et al. 2016).
These recommendations are intended for health prac-
titioners involved in auditory and tinnitus research. Our 
intention, which originated during networking in the Euro-
pean consortium TINNET, is to facilitate the formation of 
a collaborative international consortium and to develop a 
stratified collection and storage of human samples with cor-
responding medical data.
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Increasing Genetic Knowledge About Hearing 
Disorders and Psychological Comorbidities Facilitates 
Understanding of the Molecular Basis of Tinnitus
Basic knowledge about tinnitus genetics is being acquired 
rather slowly (Vona et al. 2017), in particular when compared 
with other auditory disorders such as hearing loss. As of yet, 
a large number of genetic mutations leading to hearing loss 
have been identified, and their number continues to grow (Kor-
ver et al. 2017). Many of these mutations are responsible for 
congenital hearing loss and can affect genes that are associated 
with autosomal recessive or dominant forms of hearing loss. 
For instance, many well-known mutations have been reported in 
genes encoding autosomal recessive hearing loss such as GJB2, 
GJB3, and GJB6, encoding gap junction proteins; MYO3A, 
MYO7A, and MYO15A, encoding molecular motor proteins; 
OTOF encoding inner ear-specific synaptic protein otoferlin, or 
OTOG encoding a key protein of the extracellular matrix in the 
inner ear; as well as genes associated with autosomal dominant 
hearing loss such as KCNQ4 or MYH14. For a complete list of 
genes, please see the study by Korver et al. (2017) or the fol-
lowing regularly updated website (http://hereditaryhearingloss.
org). Not surprisingly, the epigenetic control of gene expres-
sion appears equally important for proper auditory function. A 
recent study demonstrated the contribution of gene methylation, 
histone modification, and regulatory micro-RNAs to the devel-
opment and functioning of the inner ear (Layman & zuo 2014).
While there has been a substantial advance in the genetics 
of hearing loss, knowledge about the genetic basis of psycho-
logical disorders also progressed thanks to joint clinical efforts 
of large consortiums (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium 2014; Marshall et al. 2017). 
For instance, genetic mutations leading to changes in calcium 
channel signaling were commonly found in autism, attention 
deficit hyperactivity disorder, bipolar disorder, major depres-
sion, and schizophrenia (Cross-Disorder Group of the Psy-
chiatric Genomics Consortium 2013). Troublesome tinnitus 
is often accompanied by psychological comorbidities such as 
depressive symptoms, anxiety, and most importantly increased 
stress perception. An interesting genetic study of tinnitus could 
explore the relationship between promoter polymorphisms of a 
serotonin transporter and stress that may influence the develop-
ment of depressive symptoms (Karg et al. 2011). Although an 
association was found between allelic variants of the SLC6A4 
gene encoding the serotonin transporter promoter and the psy-
chological distress caused by tinnitus, these findings have not 
yet been replicated in an independent cohort (Deniz et al. 2010).
Because anxiety and depression are frequently observed 
associated with tinnitus (Trevis et al. 2017) and differences in 
personality including neuroticism are associated with several 
noncoding variants (Lo et al. 2017), it is necessary to design 
genomic studies controlling these comorbidities (such as hear-
ing loss or anxiety) to obtain comparable groups.
Collaborative Multicenter Genetic Projects
Human biobanks and genetic research databases (HBGRD) 
allow the sharing of human biological material and informa-
tion derived from its analysis. In 2009, the Organization for 
Economic Cooperation and Development (OECD) Council 
adopted a recommendation on HBGRD to foster scientific 
research (http://www.oecd.org/sti/biotech/44054609.pdf). 
The recommendation provides guidelines for the establish-
ment, management, governance, access, and discontinuation 
of HBGRDs. In general, it facilitate access to data and materi-
als for biomedical advancement while ensuring that research is 
conducted in a fully ethical way that supports human dignity 
and fundamental human rights.
To describe the genetic architecture of tinnitus and to under-
stand the complex interactions between hearing loss and tinnitus 
development, a large multicenter effort is necessary (Cederroth et 
al. 2017). Learning from other complex disorders, one can esti-
mate that tens of thousands of subjects would be required to reach 
satisfactory statistical power for a GWAS. For instance, in a study 
where calcium channel signaling was determined as a common 
denominator of multiple psychiatric conditions, over 60,000 par-
ticipants were enrolled by a large consortium consisting of 800 
investigators from 38 countries (Cross-Disorder Group of the Psy-
chiatric Genomics Consortium 2013). This prompted researchers 
to call for the involvement of international professional health-
care providers for tinnitus patients in such a project (Cederroth 
et al. 2017). The recent European Union-funded tinnitus net-
works (TINNET1, European School for Interdisciplinary Tinni-
tus Research (ESIT)2 and Tinnitus-Action (TIN-ACT)3) would 
address the project’s challenges, as these are comprised members 
with primary interests in tinnitus from several European countries.
Large, multicenter biobanking platforms are necessary to 
perform omics-studies targeting tinnitus (genomics, epigenom-
ics, transcriptomics, and metabolomics). Various scientific asso-
ciations have put together their own guidelines about DNA and 
tissue banking, and the Council for International Organizations 
of Medical Sciences (CIOMS), recognizing the importance of 
biobanks for epidemiological research, revised its guidelines in 
2005 to integrate relevant issues from the biobank debate. The 
United Nations Educational, Scientific and Cultural Organization 
(UNESCO, Paris, France) adopted the International Declaration 
on Human Genetic Data in October 2003, and France, Germany, 
Canada, and Switzerland have all issued their own guidelines for 
biobanks or genetic databases (Elger & Caplan 2006).
The main aims of this publication are to provide biobank-
ing recommendations for clinicians and tinnitus researchers. We 
describe the main steps for collecting, processing, and storing 
biological samples for genetic studies on tinnitus and hearing 
loss. Such recommendations are a cornerstone in the initiation 
of large-scale studies.
DESIGN OF GENOMIC STUDIES WITH 
BIOLOGICAL SAMPLES
The design and execution of genomic studies using samples 
obtained from human subjects must follow certain steps, which 
are presented in Figure 1 and discussed in detail below.
Ethical Approval
All research involving human subjects should be conducted 
in accordance with three basic ethical principles, namely, 
respect toward individuals, beneficence, and justice. It is gener-
ally agreed that these principles, which have equal moral force, 
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studies. Research with human subjects should be carried in 
accordance with a protocol that clearly states: (i) the aim of the 
research; the reasons for performing research in humans; (ii) the 
nature and degree of any known risks to the subjects; (iii) the 
sources from which it is proposed to recruit subjects and how; 
and (iv) the means for ensuring that any subjects participation 
is voluntary and that consent will be collected in written form 
(CIOMS, 2016)4. As mentioned before, all proposals for con-
ducting research involving human subjects must be submitted 
for review of their ethical acceptability to at least one ethical 
review board (ERB). Any direct financial or other material ben-
efits that may derive from the research should be contingent on 
the outcome of ERB review. The investigator must obtain their 
approval or clearance before undertaking the research. Consid-
ering the public interest in the use of human biological samples 
and data in biomedical research, the policies state a number of 
duties, which the institutions responsible for the collection and 
storage of samples have to respect, namely: (i) to properly con-
serve the samples; (ii) to manage the samples and the derived 
genetic data, (iii) and to control their use and distribution (Shek-
elle et al. 2013). All these aspects should be consistent with the 
new European General Data Protection Regulation (http://www.
eugdpr.org).
Written Informed Consent
An informed consent form is a document signed by the par-
ticipant after a dialogue between patients/donors and health care 
practitioners/researchers concerning the consequences, harms, 
benefits, risks, and expected results from the planned study 
(Shekelle et al. 2013). Such a document is required to confirm 
the individual’s consent that his/her samples and data will be 
collected, stored in a biobank to facilitate the analysis, and 
possibly shared with consortium partners, according to a spe-
cific material transfer agreement. The consent form is the first 
guarantee of patient’s data confidentiality because the results 
obtained from research studies might potentially have an impact 
not only on the participants themselves but also on the families, 
communities, and populations to which they belong.
The informed consent form consists of two parts: the infor-
mation sheet and the consent certificate5. The information sheet 
explains to prospective participants the nature of the research 
project, why they were chosen as candidates for the research, 
what risks and benefits exist, what options are associated with 
the research, and what rights they have as research subjects. 
The consent form must include the expression of the free and 
informed authorization for using their own biological samples 
and additional authorization for the collection of derived data 
for research purpose. The consent form should also include the 
name of the institution that will receive biological material or 
data for analysis, as well as information specifying that the par-
ticipant can retract from the study at any time, with or without 
the removal of samples or data from the biobank or the database.
The WHO recommends that consent forms should be written 
using language at the level of a local 6th/8th grade student, with 
short sentences and paragraphs, simple terms and concepts, 
and technical information explained in nontechnical ways6. The 
consent form consequently contains accurate and precise infor-
mation that is easy to follow, presented in a clear layout, with 
white-space borders, and fonts that are easy to read.
Sensitive issues about how much information a participant 
should receive, how to collect consent in a way that is respect-
ful for a local culture, how to collect the consent of minors, or 
whether community or group consent is required in some cir-
cumstances should be considered. Not every detail needs to be 
discussed in the consent form, but all details needed for a par-
ticipant to make a decision about participation in the study must 
be provided; investigators understand that ERBs must assist in 
the forms’ development and approval.
Genetic databases are often presented as key biomedical 
resources that enable researchers to perform a diverse range 
of research projects. As a consequence, participants must 
be informed that their samples could possibly be used in the 
future for other research purposes that are presently unforeseen. 
European policies adopt different views on how “specific” the 
informed consent should be, ranging from recommending a 
broad consent to a consent specifying all future uses. One pos-
sibility is to offer to contact the participant when a sample is 
intended to be used for a purpose other than what was initially 
agreed on in the consent form. In any case, we recommend add-
ing the specific information about how will the sample be pseu-
doanonymized by a biobank.
CHOICE OF MATERIAL TO BE USED FOR 
GENETIC RESEARCH
Although DNA or RNA can be obtained from any biologi-
cal sample, several factors must be considered in clinical prac-
tice. Blood and saliva samples are the most common source 
of DNA and RNA. A standardized operating procedure and 
quality controls must be implemented for any type of biologi-
cal sample. Traceability from a coded sample to the biobank 
and finally to the genomic facility is essential. The source of 
DNA/RNA should be the same throughout the study to maintain 
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sample homogeneity and reliability of the results. Gene expres-
sion (mRNA) or epigenetic markers are cell-specific and tran-
scriptome or epigenetic studies in DNA obtained from saliva 
or blood samples are inappropriate to investigate patients with 
hearing loss or tinnitus; thus, different sources of DNA or RNA 
could induce a bias. Appropriate sample labeling is an impor-
tant initial step that ensures a blind code with reference to the 
date of collection, location, and clinical information. Labeling 
must be done using appropriate materials, for example, perma-
nent and ethanol-resistant markers.
Blood Samples
Blood is routinely used in research as a source of DNA or 
RNA. The most common way is to draw the blood using eth-
ylenediaminetetraacetic acid (EDTA) Vacutainer system (or 
similar) and keep the samples refrigerated at +4 °C for up to 
24 hr or in a freezer at −80 °C for longer preservation. However, 
when long-term viability of samples is necessary (for instance, 
for purified lymphocytes or other blood cells), storage in liquid 
nitrogen can be required.
The advantage of using blood for genetics studies is the 
small amount needed to extract DNA (3 to 5 mL are sufficient). 
Blood can also be collected on paper cards (Whatman Flinders 
Technology Associates [FTA] cards) allowing its maintenance 
at room temperature for at least 80 days (Dobbs et al. 2002) or 
up to 5 years, according to the manufacturer; however, the DNA 
yield is lower compared with using peripheral blood.
Buccal Swab
A buccal swab is among the fastest methods of collecting 
biological samples from individuals. The greatest advantage in 
swab collection is that it generally does not require medically 
trained personnel; however, the amount of DNA obtained may 
be not enough to conduct genomic studies. The first step for 
an effective buccal swab sample collection is to ensure that the 
subject’s mouth is thoroughly rinsed. Participants are advised 
to restrain from eating or drinking for 2 hr before the collection 
of buccal cells. Different factors, such as individual’s diet, oral 
hygiene, oral flora, and smoking habits, influence the quality of 
extracted DNA/RNA. It is also important not to touch the teeth, 
the lips, or any surface before placing the swab in the transport 
tube. Buccal swab samples can be stored for up to 2 weeks at 4 
°C before processing for DNA extraction. Foam-tipped, cotton-
tipped, or flocked swabs are common types of swab collectors. 
Foam-tipped swabs can range in size from small to large, being 
selected according to the need and purpose, in order to mini-
mize the subject’s discomfort or collect high amounts of cells.
Saliva
Saliva is another source of a high-quality DNA and can be 
used for genetic studies. Up to 74% of DNA obtained from 
saliva samples originates from the white blood cells (Thiede 
et al. 2000)7. The quality and quantity of DNA extracted from 
a saliva sample must meet the same standards as those estab-
lished for blood samples, and DNA obtained from saliva has 
been extensively used for exome-sequencing studies (zhu et al. 
2015). DNA extraction kits for saliva samples that ensure the 
highest integrity and prevent rapid DNA degradation by local 
enzymes and bacteria should be considered. Several commer-
cially available products have been identified in multiple studies 
as ensuring the highest integrity of extracted salivary DNA8.
Other Types of Samples
Although other biological material could be used for obtain-
ing DNA/RNA, such as those used for the identification of indi-
viduals in forensic studies (e.g., FTA cards, hair, scats, feces, 
or bone fragments), we do not recommend these materials for 
genetic studies. Although samples of the inner ear or brain tis-
sues would be very interesting for gene expression studies, these 
are extremely rare and for ethical reasons difficult to obtain dur-
ing surgical procedures or postmortem.
COLLECTION OF BIOLOGICAL SAMPLES
Collecting Samples to Analyze DNA
DNA is a two-stranded long molecule containing our unique 
genetic code. Although DNA has a double-helix shape, which 
makes it more resistant to degradation than single-stranded 
RNA, it is important to treat the samples carefully and pro-
cess them in a timely manner. As mentioned above, quality 
DNA samples for genetic studies can be obtained from whole 
blood, saliva, or buccal swabs. It is our recommendation to use 
samples that are as fresh as possible, meaning that the sample 
should be processed within 24 hr after collection. If for any rea-
son that would not be possible (due to shipment or other issues), 
whole blood and saliva should be immediately stored at +4 °C, 
at which the sample will be stable up to 7 days. For a long-term 
storage, saliva can be frozen at −20 °C for up to 4 months—
after that time, samples should be stored at −80 °C. Of note, 
whole blood EDTA tubes should not be frozen if stored for the 
intended purpose of genomic DNA isolation because freezing 
EDTA tubes reduces the DNA quality and quantity.
Collecting Samples to Measure Gene Expression (RNA)
Samples that are processed for gene expression analyses need 
to be treated with extreme caution, as RNA decay occurs much 
faster than that of DNA. RNases are enzymes that destroy RNA, 
and these are present in bodily fluids, including saliva, tears, and 
sweat. This is the reason why touching the samples with bare 
hands or breathing in the direction of the sample may degrade the 
RNA in seconds. This is also why one should protect the samples 
by wearing powder-free nitrile gloves and a mouth mask. Fortu-
nately, the scientific market offers special reagents that stabilize 
RNA. These reagents include RNAlater and Allprotect Tissue 
Reagent. The samples (blood and buccal swab) should be placed 
in the RNase-free tube containing one of the reagents, closed, and 
stored submerged in a protective solution for up to 6 months at 
2 to 8 °C (fridge) or up to 7 days between +15 °C and +25 °C.
HOW TO PROCESS THE SAMPLES?
For both DNA and RNA extraction, it must be emphasized 
that specialized equipment will be necessary: micropipettes, 
centrifuges, and DNase-free and RNase-free pipette tips and 
tubes.
7 ht tp: / /blog.dnagenotek.com/blogdnagenotekcom/bid/88550/
Can-saliva-replace-blood-for-DNA-collection-analysis-Part-1-of-3.
8 http://connect.f isherbioservices.com/biosample-collection-kit- 
design-and-production-guide-for-clinical-trials.
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In the absence of such equipment, the unprocessed samples 
should be directly shipped to the biobank or genomic center for 
their processing.
Isolation of DNA
When isolating DNA, it is important to take the source of 
tissue into account. We list the available kits for DNA extrac-
tion in Table 1. Although there are many options, the QIAamp 
DNA Mini Kit (Qiagen) is widely used as it provides silica-
membrane–based nucleic acid purification from swabs and 
whole blood. High and consistent yields can be achieved when 
following the manufacturer’s protocol. If saliva is the starting 
material for genomic DNA extraction, many kits are specialized 
and have their own collection tubes to maintain and stabilize 
the DNA for longer periods of time, for example, the Oragene 
2DNA kit (DNA Genotek), which allows saliva specimens to be 
stored for years at room temperature without DNA degradation.
Isolation of RNA
RNA may show signs of significant degradation in as little 
as 30 min after collection (Sheldon et al. 2011). If the sample 
intended for RNA processing is placed and stored in one of the 
two solutions mentioned earlier (RNAlater or Allprotect Tis-
sue Reagent, both developed by Qiagen) then the best RNA 
isolation method will be using RNeasy Mini or Micro Kit (Qia-
gen) following the protocol strictly provided by the manufac-
turer (protocol B). If, however, RNA is to be isolated from fresh 
samples, then a method of choice could be used.
Quality Controls for DNA and RNA
Sample quality is critical in genomic experiments, and it 
should always be checked before starting a genomics protocol. 
A quality control can be performed using the Agilent Bioana-
lyzer system for both DNA and RNA. Quantification of DNA/
RNA can also be performed using the NanoDrop or Qubit 
assays. Quality control of genomic DNA could be done using 
Bioanalyzer or a 1% agarose gel. High-quality genomic DNA 
should appear as a major band of 10 to 20 kb on the gel.
For DNA, we recommend the Qubit fluorometric quantita-
tion. One can also check the OD260/280 ratio of DNA or RNA 
using a NanoDrop. Pure DNA that is uncontaminated by pro-
teins has an A260/280 ratio of 1.8, whereas pure RNA has an 
A260/280 ratio of 2.0. It is also of benefit to measure absorp-
tion at 230 nm, as high A230 values indicate contamination with 
salts or organic solvents.
Total RNA samples for RNAseq or microarray should be 
free of proteins, DNA, phenol, ethanol, and salt. RNA integrity 
must be checked by running RNA samples on an Agilent Bioan-
alyzer. If there is significant degradation (when RNA Integrity 
TABLE 1. Commercially available DNA and RNA extraction kits
Kit Name Manufacturer Tissues Processed
Genomic DNA extraction   
  Blood DNA Mini Kit Plus VWR Blood
  ChargeSwitch gDNA Blood Kits Thermo Fisher Scientific Blood
  GenElute Blood Genomic DNA Kit Sigma-Aldrich Blood
  GenElute Mammalian Genomic DNA Miniprep Kit Sigma-Aldrich Saliva
  QIAamp DNA Mini Kit QIAGEN Blood, buccal swab, saliva
  Quick-DNA Miniprep Plus Kit Zymo Research Blood
  MagMax DNA Multi-Sample or Multi-Sample Ultra Kit Thermo Fisher Scientific Blood, buccal swab, saliva
  NucleoSpin Blood, Blood L or Blood XL Kit Machery-Nagel Blood
  PAXgene Blood DNA Kit QIAGEN Blood
  prepGEM Blood Kit VWR Blood
  prepGEM Saliva Kit VWR Buccal swab, saliva
  PureLink Genomic DNA Mini Kit Thermo Fisher Scientific Blood
  Saliva DNA Isolation Kit Norgen Biotek Corp. Saliva
  Wizard Genomic DNA Purification Kit Promega Blood
  ZymoBIOMICS DNA Miniprep or DNA/RNA Mini Kit Zymo Research Buccal swab, saliva
RNA extraction   
  Blood RNA Miniprep Kit VWR Blood
  E.Z.N.A. Blood RNA Midi Kit VWR Blood
  GenElute Total RNA Purification Kit Sigma-Aldrich Blood, saliva
  High Pure RNA Isolation Kit Roche Blood
  MagMAX for Stabilized Blood Tubes Thermo Fisher Scientific Blood
  NucleoSpin RNA Machery-Nagel Saliva
  NucleoSpin RNA Blood Machery-Nagel Blood
  PAXgene Blood RNA Kit QIAGEN Blood
  QIAamp RNA Blood Mini Kit QIAGEN Blood
  Quick-RNA Whole Blood Zymo Research Blood
  RiboPure RNA Isolation Kit Thermo Fisher Scientific Blood
  RNeasy Mini, Micro, Midi or Maxi Kit QIAGEN Blood
  RNeasy Protect Saliva Mini Kit QIAGEN Saliva
  SV Total RNA Isolation System Promega Blood
  Total RNA Purification Kit Norgen Biotek Corp. Blood, saliva
  ZymoBIOMICS DNA/RNA Mini Kit Zymo Research Buccal swab, saliva
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Number, or RIN, is below 7.0), we recommend obtaining new 
RNA samples of satisfactory quality.
STORAGE OF DNA AND RNA SAMPLES
The storage of biological samples is a key challenge that 
begins during sample collection, as sample integrity is a fac-
tor of higher relevance. Ideally, biological samples should 
be processed immediately after collection, but in practice, 
the majority of them will be stored. Biological samples must 
be stored in fully qualified, temperature-controlled storage. 
Any area in which biological samples are stored must remain 
within a controlled temperature range (e.g.: −196 °C; −80 
°C; −20 °C; 2.0 to 8.0 °C; 15.0 to 25.0 °C), depending on 
biological samples’ requirements that range from controlled 
room temperature to cold storage, ultra-low-temperature 
storage and vapor-phase liquid nitrogen storage. Sample 
temperatures must be monitored, and the sample storage 
facility must be supported by multiple backup systems and 
an inventory tracking system.
The major difficulty in collecting biological material for 
genetic purposes is keeping the DNA from degrading. The main 
degrading agents of DNA in most samples are enzymes with 
DNase activity, present in the sample or produced by growing 
microorganisms; therefore, a procedure for enzyme inactivation 
must be used. Table 2 summarizes the effect of temperature on 
DNA storage. Several options exist for storing samples accord-
ing to the regulations and resources of local facilities. We rec-
ommend preparing stock and aliquots with diluted samples to 
prevent repeated freeze–thaw cycles. Several possibilities exist 
for storing samples according to the local facilities.
Storing at Room Temperature
We recommend storing the samples at room temperature 
(even those in protective solutions) for as briefly as possible. 
The reasons are multiple, but the primary reason is that room 
temperature may vary widely between 16 and 35 °C, depending 
on time of year and availability of air conditioning. We recom-
mend the following storage temperatures to create as uniform 
processing conditions as possible.
Storing at +2 to +8 °C
This is the most common type of storage, and it provides an 
almost constant temperature that is available in all healthcare 
units. When using AllProtect, DNA samples are stabilized for 
an extended storage period of up to 6 months without damaging 
the samples. RNA samples should not be stored at +2 to +8 °C.
Storing at −20 °C
Storage at −20 °C is recommended for purified DNA or puri-
fied RNA (when in ethanol). Aqueous RNA samples cannot be 
stored for more than 3 months.
Storing at −80 °C
Storage at −80 °C is the most advisable approach for long-
term storage of all purified nucleic acids, but this is likely the 
least available freezer in clinical settings.
SAMPLE SHIPMENT
The international nature of collaboration requires stream-
lined shipping logistics to reduce specimen quality issues. Sam-
ple collection and shipping protocols are important to minimize 
potentially detrimental biomolecular artefacts that are the result 
of delayed sample processing. If samples are not processed and 
shipped according to best-practice standard operating proce-
dures, downstream applications of collected samples could be 
impacted (Hatzis et al. 2011).
Shipment of human samples from clinical centers to bio-
banks must comply with federal packaging (country-specific) 
and labeling regulations. The package should include only the 
coded biological specimen. Packages must be clearly marked 
with sender and recipient addresses. Utilizing express or over-
night courier services is highly recommended if possible. Pack-
aging should follow the best practice guidelines of the courier9.
Biological samples intended for extraction and analysis of 
genomic DNA should be shipped either at room temperature 
or chilled and expedite shipped to the biobank. Blood or saliva 
samples for RNA extraction and analysis should be collected 
TABLE 2. Recommendations for DNA and RNA storage
 Room Temperature +2 to +8 °C −20 °C −80 °C Liquid Nitrogen
Buccal 
swab
Inadvisable Up to 2 wk    
Saliva Depending on the 
collection tube 
between 24 hr and 
years for DNA and 
up to 60 days for 
RNA
Depending on the 
collection tube 









Whole blood Up to 24 hr Up to 7 days Inadvisable. It is better 
to isolate cell types 
and store them 
properly before use. 
Short-term storage
Inadvisable. It is better to 
isolate cell types and 
store them properly 
before use. Mid-term 
storage
Inadvisable. It is better to 
isolate cell types and 
store them properly 








Recommended for mid- 
to long-term storage




Never Inadvisable but stable 
for several days
Up to 6 mo Recommended for mid- 
to-long-term storage
Best approach for long- 
term storage
9 http://www.who.int/ihr/publications/WHO_CDS_CSR_EDC_2000_4/en/.
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in tubes containing additive RNA-stabilizing chemicals (0.5 mL 
of EDTA blood with 1.3 mL RNAlater or PAXgene blood vacu-
tainers; Weber et al. 2010). These tubes should be shipped on 
dry ice for overnight delivery. This procedure has demonstrated 
higher RNA yields and integrity and is recommended for imple-
mentation into biobanking protocols where RNA isolation will 
follow.
As a final best-practice standard operating procedure for 
sample collection and shipment (unless the biobank is located 
locally with a guarantee for same-day pick-up and delivery), 
it is highly recommended to plan collection and shipment of 
samples to avoid extended delays in transit due to weekends or 
holidays. Unplanned or anticipated delays can drastically influ-
ence sample quality.
CLINICAL INFORMATION
As tinnitus is a symptom of multiple conditions involving 
numerous audiological and psychological comorbidities, we 
believe that an effective genetic study could only emerge from 
a detailed phenotyping strategy allowing the classification and 
selection of individuals with a homogeneous tinnitus pheno-
type (Lopez-Escamez et al. 2016). The Human Phenotype 
Ontology (HPO) Project provides a standardized vocabulary 
of phenotypic abnormalities encountered in human diseases 
(Köhler et al. 2017). Each term in the HPO describes a phe-
notypic abnormality, such as hearing loss (HPO:0000365) or 
tinnitus (HPO:0000360). However, the heterogeneity in tin-
nitus phenotype is not considered, with the exception of pul-
satile tinnitus (HPO: 00008629), and further additional terms 
in hearing and tinnitus should be included, such as those that 
distinguish unilateral from bilateral tinnitus. Moreover, psy-
chological comorbidities (anxiety and depression) and mental 
health status should be included in clinical questionnaires to 
obtain a comprehensive phenotype, as these conditions dis-
play a genetic contribution.
The main tinnitus variables should be defined in the protocol 
of the study and a core set of relevant questionnaires included 
(Müller et al. 2016), along with a number of recommended 
audiological procedures (Table 3). The clinical information to 
be collected must be easy to obtain and should be stored in a 
secure database with coded access according to national/Euro-
pean regulations on personal data protection.
SECURITY AND PROTECTION
A contingency plan should be established to access, elimi-
nate, and share data with potential collaborators, keeping per-
sonal data secure and guaranteeing the right of each individual 
to withdraw or participate in future studies.
The disposal of DNA, RNA, or any human biological sample 
is governed by international regulation in biomedical research, 
and all samples should be handled according to ERB and 
national/European regulations on health information or HIPAA 
Privacy Rule in the United States (https://www.hhs.gov/hipaa/
index.html).
Access to Data and Transfer to the Consortium
Data from biological databases cannot be accessed for non-
research purposes by insurers, employers, law enforcement 
agencies, or other civil-law agencies (OECD, 2009).
Different access forms to data are possible, according to 
the main goal of the study. Essentially, two possibilities are 
accepted: database querying is performed by the staff who 
returns collected results to the researchers, or researchers 
directly access databases to query only certain aspects of the 
data held by the database. Access to genetic data must be con-
sistent with the research protocols, the participant’s informed 
consent, and conform to the privacy and confidentiality poli-
cies established in the ERB TINNET consortium will facilitate 
access to anonymized genomic data according to EU regula-
tion on data protection.
Secured Storage of Human Biological Samples and Data
The storage of biological material as a collection for future 
research (including genetics research) should be considered as 
an option, and in case of a positive decision, permission must 
be obtained from the ERB. However, the essential topic is that 
the written consent form has to address the issue of sample 
storage length and possibility for further research use (Wolf 
et al. 2008).
The storage of tissue samples and data either linked to the 
samples or derived from them needs to be clearly considered, 
with protection of data that contains information about the 
donor (demographic characteristics, type of disease, and out-
comes associated with the sample and its treatment) a priority.
Consequently, all protected health information must be 
considered sensitive data and addressed to ensure patient 
confidentiality, avoiding the possibility of linking genetic 
data back to a patient’s identity. Some guidelines suggest a 
de-identification of samples such that a coded sample is rela-
beled with a unique second code, while maintaining a link 
between the two codes (i.e., double-coded); or anonymiza-
tion of samples such that the link between the two codes of a 
double-coded sample is permanently deleted. While the pro-
cess of anonymization provides a maximum security, it does 
not allow for returning results, sample withdrawal, clinical 
monitoring, or patient follow-up.
TABLE 3. Minimum clinical information required for phenotyping 
patients with tinnitus for genetic studies
1.  Ethnicity
2.  Sex, date of birth
3.  Age at tinnitus onset
4.  Uni/bilateral tinnitus
5.  Psychoacoustic profile of tinnitus: pitch matching and loudness
6.  Visual-analogues scale for tinnitus annoyance*
7.  Validated tinnitus questionnaire assessing tinnitus severity (i.e., 
Tinnitus Functional Index, Tinnitus Handicap Inventory, and 
Tinnitus Questionnaire; Newman et al. 1996; Newman et al. 1998)
8.  Familial history of hearing loss or tinnitus†
9.  Hearing profile
    High-frequency pure-tone audiogram (up to 16 KHz)
    Distortion product otoacoustic emissions (DPOAEs)
    Speech comprehension score
    Tympanometry
10.  Current and past ototoxic medications
11.  Description of professional noise exposure and its duration
12.  List of comorbid conditions including psychological disorders
*Score in the past month.
†Relatives in the first and second degree.
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CONCLUDING REMARKS
We have provided detailed instructions for nongeneticist 
healthcare professionals who would like to be involved in genet-
ics research in the field of hearing science. Collaborative mul-
tidisciplinary research with a deep phenotyping of tinnitus is 
an optimal way to identify well-defined targets for the develop-
ment of effective therapies. TINNET consortium encourages all 
health professionals dealing with tinnitus patients who read this 
paper and became interested in the project to contact us directly 
(see authors information).
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